Disc Medicine Statistics
Total Valuation
Disc Medicine has a market cap or net worth of $2.37 billion. The enterprise value is $1.71 billion.
| Market Cap | 2.37B |
| Enterprise Value | 1.71B |
Important Dates
The next estimated earnings date is Thursday, November 5, 2026, before market open.
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Disc Medicine has 38.39 million shares outstanding. The number of shares has increased by 16.89% in one year.
| Current Share Class | 38.39M |
| Shares Outstanding | 38.39M |
| Shares Change (YoY) | +16.89% |
| Shares Change (QoQ) | +0.50% |
| Owned by Insiders (%) | 0.57% |
| Owned by Institutions (%) | 107.33% |
| Float | 32.91M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 5,713.19 |
| PB Ratio | 3.67 |
| P/TBV Ratio | 3.67 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 24.14, with a Debt / Equity ratio of 0.09.
| Current Ratio | 24.14 |
| Quick Ratio | 23.64 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -75.57 |
Financial Efficiency
Return on equity (ROE) is -39.08% and return on invested capital (ROIC) is -24.85%.
| Return on Equity (ROE) | -39.08% |
| Return on Assets (ROA) | -23.96% |
| Return on Invested Capital (ROIC) | -24.85% |
| Return on Capital Employed (ROCE) | -38.09% |
| Weighted Average Cost of Capital (WACC) | 15.54% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.49M |
| Employee Count | 165 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Disc Medicine has paid $310,000 in taxes.
| Income Tax | 310,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -9.04% in the last 52 weeks. The beta is 2.10, so Disc Medicine's price volatility has been higher than the market average.
| Beta (5Y) | 2.10 |
| 52-Week Price Change | -9.04% |
| 50-Day Moving Average | 74.41 |
| 200-Day Moving Average | 71.54 |
| Relative Strength Index (RSI) | 24.94 |
| Average Volume (20 Days) | 636,751 |
Short Selling Information
The latest short interest is 7.21 million, so 18.77% of the outstanding shares have been sold short.
| Short Interest | 7.21M |
| Short Previous Month | 7.37M |
| Short % of Shares Out | 18.77% |
| Short % of Float | 21.90% |
| Short Ratio (days to cover) | 14.68 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -268.41M |
| Pretax Income | -245.58M |
| Net Income | -245.89M |
| EBITDA | -268.06M |
| EBIT | -268.41M |
| Earnings Per Share (EPS) | -$6.56 |
Balance Sheet
The company has $717.75 million in cash and $60.86 million in debt, with a net cash position of $656.88 million or $17.11 per share.
| Cash & Cash Equivalents | 717.75M |
| Total Debt | 60.86M |
| Net Cash | 656.88M |
| Net Cash Per Share | $17.11 |
| Equity (Book Value) | 644.16M |
| Book Value Per Share | 16.80 |
| Working Capital | 702.40M |
Cash Flow
In the last 12 months, operating cash flow was -$197.54 million and capital expenditures -$46,000, giving a free cash flow of -$197.58 million.
| Operating Cash Flow | -197.54M |
| Capital Expenditures | -46,000 |
| Depreciation & Amortization | 355,000 |
| Net Borrowing | 29.98M |
| Free Cash Flow | -197.58M |
| FCF Per Share | -$5.15 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Disc Medicine does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -16.89% |
| Shareholder Yield | -16.89% |
| Earnings Yield | -10.39% |
| FCF Yield | -8.35% |
Analyst Forecast
The average price target for Disc Medicine is $103.17, which is 67.35% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $103.17 |
| Price Target Difference | 67.35% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |